Methods and compositions for improving in vivo survival of midbrain dopamine neurons
JP2025509780A5Pending Publication Date: 2026-04-14MEMORIAL SLOAN KETTERING CANCER CENT +2
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- MEMORIAL SLOAN KETTERING CANCER CENT
- Filing Date
- 2023-03-20
- Publication Date
- 2026-04-14
AI Technical Summary
Technical Problem
In the prior art, implanted dopamine neurons have a low survival rate after surgery, resulting in unstable therapeutic effects and may trigger an inflammatory response to the host.
Method used
The survival rate of dopamine neurons in the midbrain is increased by inhibiting p53-mediated apoptosis. Specific methods include the use of TNFα inhibitors, NFκB inhibitors or p53 inhibitors to inhibit apoptotic signaling pathways.
Benefits of technology
It significantly improves the survival rate of dopamine neurons in the midbrain, reduces apoptosis, enhances the stability and effectiveness of treatment, and reduces the inflammatory response to the host.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present disclosure provides a method for improving in vivo survival of midbrain dopamine (mDA) neurons (e.g., in vitro differentiated mDA neurons) by suppressing p53-mediated apoptosis of the mDA neurons. The present disclosure further provides a method for treating a subject (e.g., a subject suffering from neurodegeneration and / or a neurodegenerative disease of midbrain dopamine neurons), the method comprising administering one or more mDA to the subject, whereby p53-mediated apoptosis of the one or more mDA neurons is suppressed.
Need to check novelty before this filing date? Find Prior Art